KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension...(ourth quarters of fiscal2007 and for the...),Health

Date:2/15/2008

ourth quarters of fiscal 2007 and for the full fiscal year ended March 31, 2007, and for the first, second and third quarters of fiscal 2008; (15) actions by the Securities and Exchange Commission and the Internal Revenue Service with respect to the Company's stock option grants and accounting practices; and (16) the risks detailed from time-to-time in the Company's filings with the Securities and Exchange Commission; and (17) actions by the NYSE Regulation, Inc. with respect to the continued listing of the Company's stock on the New York Stock Exchange.

This discussion is by no means exhaustive, but is designed to highlight important factors that may impact the Company's outlook. We are under no obligation to update any of the forward-looking statements after the date of this release.

K-V PHARMACEUTICAL COMPANY AND SUBSIDIARIES

UNAUDITED CONSOLIDATED BALANCE SHEETS

(Dollars in thousands)

March 31,

2007 2006

ASSETS (as restated)

Current Assets:

Cash and cash equivalents $82,574 $100,706

Marketable securities 157,812 106,763

Receivables, less allowance for doubtful accounts

of $716 and $397 in 2007 and 2006, respectively 78,634 53,571

Inventories, net 91,515 71,166

Prepaid and other assets 6,571 7,012

Deferred tax asset 14,364 10,072

Total Current Assets 431,470 349,290

Property and equipment, less accumulated

depreciation 186,900 178,042

Intangible as
'/>"/>

SOURCE KV Pharmaceutical Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Related medicine news :

1. His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States
2. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
3. NUCRYST Pharmaceuticals announces year-end results
4. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
5. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
6. Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities
7. Convera(R) Expands Advanstar OnLine Business to Vertical Search Covering Pharmaceutical Industry Applications
8. American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals
9. Chesapeake to Expand and Relocate North American Pharmaceutical Packaging Operation
10. MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product
11. Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program